Sector News

Covid-19 is teaching hard lessons about China-only supply chains

March 2, 2020
Life sciences

Until about the third week of January, only a few pharmaceutical executives, drug-safety inspectors and dogged China hawks cared that a large share of the world’s supply of antibiotics depends on a handful of Chinese factories.

These include a cluster in Inner Mongolia, a northern province of windswept deserts, grasslands and unlovely industrial towns. Then came the covid-19 outbreak, and quarantine controls that locked down factories, ports and whole cities across China.

Chinese leaders insist that they are well on the way to conquering the virus, allowing them to reopen “leading enterprises and key links with important influence” in global supply chains. A victory over the novel coronavirus will once again demonstrate “the notable advantages of leadership by the Communist Party of China”, President Xi Jinping told 170,000 officials by video-conference on February 23rd. But even if all those boasts come true, foreign governments and business bosses will not quickly forget a frightening lesson: for some vital products, they depend on one country.

> Read the full article on The Economist website

Source: The Economist

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 17, 2021

SII expects WHO emergency approval of Covid-19 vaccine soon

Life sciences

The Serum Institute of India (SII) expects to soon receive World Health Organisation (WHO) emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, produced for mid and low-income countries.

January 17, 2021

Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn

Life sciences

According to the deal, Sanofi will gain full global rights to Kymab’s fully human monoclonal antibody, KY1005 that attaches to OX40-Ligand and can potentially treat various immune-mediated diseases and inflammatory ailments.

January 17, 2021

Moderna poaches Amgen vet as CCO, jump-starting commercial team as it rolls out COVID-19 vaccine

Life sciences

Moderna tapped veteran Amgen executive Corinne Le Goff to spearhead that effort as chief commercial officer.

Send this to a friend